Highly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer's disease patients

被引:0
|
作者
Matsuda, Hiroshi [1 ,2 ,6 ]
Hanyu, Haruo [3 ]
Kaneko, Chikako [4 ]
Ogura, Masato [1 ,2 ]
Yamao, Tensho [5 ]
机构
[1] Southern Tohoku Res Inst Neurosci, Drug Discovery & Cyclotron Res Ctr, 7-61-2 Yatsuyamada, Koriyama, Fukushima 9638052, Japan
[2] Fukushima Med Univ, Dept Pediat, Hikarigaoka 1, Fukushima, Fukushima 9601295, Japan
[3] Tokyo Gen Hosp, Dementia Res Ctr, 3-15-2 Egota, Nakano-Ku, Tokyo 1650022, Japan
[4] Southern Tohoku Gen Hosp, Dept Neurol, 7-115 Yatsuyamada, Koriyama, Fukushima 9638052, Japan
[5] Fukushima Med Univ, Sch Hlth Sci, Dept Radiol Sci, 10-6 Sakae, Fukushima, Fukushima 9608516, Japan
[6] Southern Tohoku Res Inst Neurosci, Metropolitan Off, Shinotemachi-Bldg,6F,621,2-2-1,Otemachi,Chiyoda K, Tokyo 1000004, Japan
关键词
Alzheimer's disease; Amyloid imaging; Tau imaging; Positron emission tomography; F-18-AZD4694; DIAGNOSIS;
D O I
10.1007/s12149-025-02018-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectiveThis study aims to accurately classify ATN profiles using highly specific amyloid and tau PET ligands and MRI in patients with cognitive impairment and suspected Alzheimer's disease (AD). It also aims to explore the relationship between quantified amyloid and tau deposition and cognitive function.MethodsTwenty-seven patients (15 women and 12 men; age range: 64-81 years) were included in this study. Amyloid and tau PET scans were performed using 18F-NAV4694 and 18F-MK6240, respectively. For each patient, amyloid and tau PET images were visually assessed and classified as either amyloid-positive or amyloid-negative, and as 18F-MK6240 Braak stage 0 (tau-negative) or Braak stages I-VI (tau-positive). Voxel-based morphometry of three-dimensional T1-weighted MRI was used to evaluate neurodegeneration. Amyloid and tau depositions were quantified using the Centiloid scale and standardized uptake value ratio (SUVR), respectively. Global cognitive function was assessed with the Mini-Mental State Examination (MMSE).ResultsPatients were categorized into seven ATN profiles. Six patients (22%) exhibited a normal AD biomarker profile, 15 patients (56%) fell within the Alzheimer's continuum, and 14 patients (52%) were diagnosed with AD. Additionally, six patients (22%) displayed non-AD pathological changes. Positive and negative findings of amyloid and tau PET were concordant in 24 patients (89%). Among the 14 patients diagnosed with AD, the Centiloid scale for amyloid deposition did not show a significant negative correlation with MMSE scores (r = 0.269, p = 0.451). In contrast, the SUVR for tau deposition in the neocortex exhibited a significant negative correlation (r = -0.689, p = 0.014), while tau deposition in the mesial temporal region did not show a significant correlation (r = 0.158, p = 0.763).ConclusionHighly specific amyloid and tau PET scans, along with MRI, can be utilized to accurately classify ATN profiles in patients with cognitive impairment and suspected AD. The discordance in amyloid and tau PET findings in three patients allowed for a more precise AD diagnosis. Furthermore, tau PET imaging provided insight into the propagation of tau deposition in the neocortex beyond the mesial temporal region, which is associated with cognitive decline.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease
    Svedberg, Marie M.
    Rahman, Obaidur
    Hall, Hakan
    NUCLEAR MEDICINE AND BIOLOGY, 2012, 39 (04) : 484 - 501
  • [22] Biomarkers for Alzheimer's disease beyond amyloid and tau
    Zetterberg, Henrik
    Schott, Jonathan M.
    NATURE MEDICINE, 2019, 25 (02) : 201 - 203
  • [23] Biomarkers for Alzheimer’s disease beyond amyloid and tau
    Henrik Zetterberg
    Jonathan M. Schott
    Nature Medicine, 2019, 25 : 201 - 203
  • [24] Amyloid-β and Tau at the Crossroads of Alzheimer's Disease
    Gallardo, Gilbert
    Holtzman, David M.
    TAU BIOLOGY, 2019, 1184 : 187 - 203
  • [25] Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment
    Chandra, Avinash
    Valkimadi, Polytimi-Eleni
    Pagano, Gennaro
    Cousins, Oliver
    Dervenoulas, George
    Politis, Marios
    HUMAN BRAIN MAPPING, 2019, 40 (18) : 5424 - 5442
  • [26] Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease
    Imbimbo, Bruno P.
    Watling, Mark
    Imbimbo, Camillo
    Nistico, Robert
    ALZHEIMERS & DEMENTIA, 2023, 19 (10) : 4729 - 4734
  • [27] PET imaging of amyloid in Alzheimer's disease
    Nordberg, A
    LANCET NEUROLOGY, 2004, 3 (09): : 519 - 527
  • [28] Deep learning detection of informative features in tau PET for Alzheimer's disease classification
    Jo, Taeho
    Nho, Kwangsik
    Risacher, Shannon L.
    Saykin, Andrew J.
    BMC BIOINFORMATICS, 2020, 21 (Suppl 21)
  • [29] Deep learning detection of informative features in tau PET for Alzheimer’s disease classification
    Taeho Jo
    Kwangsik Nho
    Shannon L. Risacher
    Andrew J. Saykin
    BMC Bioinformatics, 21
  • [30] Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Results in Patients with Suspected Alzheimer's Disease
    Lojo-Ramirez, Jose Antonio
    Guerra-Gomez, Miriam
    Marin-Cabanas, Alba Marta
    Fernandez-Rodriguez, Paula
    Sanchez-Arjona, Maria Bernal
    Franco-Macias, Emilio
    Garcia-Solis, David
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 97 (01) : 447 - 458